Study of Skin Reactions in Adults Receiving First-Line Chemotherapy with Thoracic Implantable Catheter Chambers

What this Trial Is About

Researchers are studying skin reactions related to thoracic implantable catheter chamber ICC dressings in patients newly treated with systemic chemotherapy. The ICC is widely used in oncology to administer treatments without damaging veins, but it may cause complications such as infections and skin reactions including redness, itching, and dermabrasion. This study aims to confirm the frequency of these skin reactions in a large group and explore factors like patient characteristics, treatment side effects, dressing application, duration, and climate conditions that might affect skin tolerance. The study will follow a group of 500 patients receiving first-line chemotherapy using a thoracic implantable catheter chamber. Data will be collected to observe the incidence and risk factors for skin reactions linked to the dressings. The research will also evaluate the consequences of these reactions on treatment management, infection risk, and patient comfort. The study includes patients from multiple centers, including a site in the French West Indies, to examine differences across skin types and environmental conditions. Participants will be monitored over an average of 18 months to measure the occurrence of skin reactions and their impact on therapy and quality of life. The study involves regular assessments to identify risk factors and track any treatment changes or complications such as catheter infections. Researchers will also assess patient comfort and satisfaction related to skin reactions. This observational research complements existing studies on catheter infections and aims to improve care practices for patients using ICC dressings.

Skin Reactions Related to Thoracic Implantable Chamber Dressings